Pliant Therapeutics, Inc..
PLRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for fibrotic diseases. Their lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule selective inhibitor of αvβ6 integrin, targeting idiopathic pulmonar...Show More
Better Health for All
-20
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies.
1
It aims to prevent or reverse fibrosis and restore organ function.
2
Its lead product candidate, bexotegrast, showed positive results in Phase 2a trials for idiopathic pulmonary fibrosis (IPF)
3
and primary sclerosing cholangitis (PSC),
4
demonstrating improvements in FVC, liver stiffness, and ALP levels,
5
and was well tolerated for up to 40 weeks with no drug-related serious adverse events.
6
However, the Phase 2b/3 BEACON-IPF trial for bexotegrast was discontinued due to an imbalance in unadjudicated IPF-related adverse events between treatment and placebo groups, with a mean exposure duration of approximately 17 weeks.
7
The company voluntarily paused enrollment and dosing following a Data Safety Monitoring Board recommendation
8
and is informing global regulatory authorities.
9
Pliant aims to reach approximately 150,000 IPF patients in the US and over 3 million worldwide, and 30,000-45,000 PSC patients in the US.
10
The company works with Black Health Matters to enhance diversity in clinical trials and expand outreach to Black and African American communities.
11
Pliant's Code of Business Conduct and Ethics requires maintaining confidentiality of information
12
and prohibits scientific misconduct.
13
The company offers a competitive suite of benefits to its 171 full-time employees, including health insurance and a 401k,
14
and supports women's recovery from substance use, which includes mental health aspects.
15
Fair Money & Economic Opportunity
0
Pliant Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for fibrotic diseases.
1
Its business model centers on research and development, collaborative partnerships, pipeline development, regulatory strategy, and market access.
2
The company does not offer lending, deposit, or other financial services to consumers, manage customer finance data, or operate financial service access points.
3
Therefore, all KPIs related to fair money and economic opportunity are not applicable to its core business operations.
4
Fair Pay & Worker Respect
20
For fiscal year 2024, the CEO to median employee pay ratio was 22:1.
1
The CEO's total compensation was $6,614,704, and the median employee compensation was $301,141.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Pliant Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-60
Pliant Therapeutics has a whistleblower policy in place.
1
The company is subject to the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws, which require the maintenance of accurate books and records and internal accounting controls.
2
However, the policy's training frequency and effectiveness metrics are not specified. The company has an ESG Risk Rating of 37.7, ranking 720 out of 847 in the Pharmaceuticals industry, indicating a bottom quartile controversy score.
3
Kind to Animals
-70
Pliant Therapeutics has significant involvement in animal testing.
1
No specific corporate policy regarding animal testing, reduction targets, or the volume of animals used annually is publicly disclosed by the company.
2
While the FDA Modernization Act 2.0 removed the statutory requirement for animal testing in Investigational New Drug applications, and the FDA released a roadmap in April 2025 to reduce animal testing, there is no evidence of Pliant Therapeutics' direct engagement in these policy changes or advocacy for higher animal welfare standards.
3
The company's controversy level is reported as 'None'.
4
No War, No Weapons
0
Pliant Therapeutics, Inc. is a biopharmaceutical company.
1
The company has no involvement in military contracting, controversial weapons, or small arms.
2
There is no evidence of revenue from arms or defense contracts.
3
The company's core business does not involve mineral inputs, dual-use technologies, or procurement from conflict zones, making several KPIs not applicable.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs.
1
While articles mention the company's commitment to environmental sustainability and the growing importance of ESG factors, they explicitly state that specific metrics, targets, or performance data for Pliant Therapeutics, Inc. are not provided.
2
An SDG Transparency Score is mentioned but does not map to any KPI in the rubric.
3
Respect for Cultures & Communities
0
No evidence available to assess Pliant Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Pliant Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
Pliant Therapeutics, Inc. has no specific regulatory actions, violations, fines, or compliance issues mentioned in the provided articles.
1
For all other waste and sustainable product KPIs, there is no specific data available.
2